Journal: Journal of proteomics

Article Title: Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques

doi: 10.1016/j.jprot.2014.05.009

Figure Lengend Snippet: Pigtailed macaques entered in the experiment C. trachomatis serovar used to infect, site of inoculation, antibiotic treatment and number of samples collected

Article Snippet: At the time the experiments were performed combination therapy with different agents was included. table ft1 table-wrap mode="anchored" t5 caption a7 # Pigtaile d macaqu es Inoculati on site # serum samples before inoculati on Chlamy dia serovar # of inoculatio ns # serum samples after inoculati on # Pigtaile d macaqu es Treatment # serum sampl es after tx 15 Fallopian tubes 6 Doxycyclin e: 2.2mg/kg/d ay orally, 10 days Doxycyclin e: 16 9 6 × 10 6 Serovar D (PO124) 3X 13 1 2.2mg/kg/d ay orally, 10 days + Triamcinolo ne: 0.2mg/kg each, 3 days 1 2 Placebo x 10 days Doxycyclin 9 2 5 × 10 6 Serovar E 2X 3 2 e: 2.2mg/kg/d 3 (MTW47 7) ay orally, 10 days Doxycyclin e: 1 2.2mg/kg/d ay orally, 10 days Doxycyclin 1 4 6 × 10 6 Serovar E 2X 6 e: 2.2mg/kg/d ay orally, (MTW47 7) 2 10 days + Triamcinolo ne: 0.2mg/kg each, 3 days 4 1 Placebo x 10 days 0 5 × 10 4 Serovar 4 Placebo x 14 days 7 10 Cervix 7 E (MTW47 7) 5X 10 3 Placebo x 14 days 0 3 5 × 10 4 Serovar E (MTW47 7) 1X 8 3 Azithromyci n: 14mg/kg each, 5 days 0 Open in a separate window Pigtailed macaques entered in the experiment C. trachomatis serovar used to infect, site of inoculation, antibiotic treatment and number of samples collected Production of C. trachomatis proteome microarray chips The C. trachomatis protein microarray chips were prepared following a three steps process: 1) PCR amplification of the 894 open reading frames (ORF); 2) in vivo recombination cloning, and 3) in vitro transcription/translation followed by microarrays chip printing (Antigen Discovery, Inc., Irvine, CA).

Techniques:

Journal: Journal of proteomics

Article Title: Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques

doi: 10.1016/j.jprot.2014.05.009

Figure Lengend Snippet: Number of monkeys (% +) that gave positive signals with the 20 immunodominant antigens following infection with C. trachomatis

Article Snippet: At the time the experiments were performed combination therapy with different agents was included. table ft1 table-wrap mode="anchored" t5 caption a7 # Pigtaile d macaqu es Inoculati on site # serum samples before inoculati on Chlamy dia serovar # of inoculatio ns # serum samples after inoculati on # Pigtaile d macaqu es Treatment # serum sampl es after tx 15 Fallopian tubes 6 Doxycyclin e: 2.2mg/kg/d ay orally, 10 days Doxycyclin e: 16 9 6 × 10 6 Serovar D (PO124) 3X 13 1 2.2mg/kg/d ay orally, 10 days + Triamcinolo ne: 0.2mg/kg each, 3 days 1 2 Placebo x 10 days Doxycyclin 9 2 5 × 10 6 Serovar E 2X 3 2 e: 2.2mg/kg/d 3 (MTW47 7) ay orally, 10 days Doxycyclin e: 1 2.2mg/kg/d ay orally, 10 days Doxycyclin 1 4 6 × 10 6 Serovar E 2X 6 e: 2.2mg/kg/d ay orally, (MTW47 7) 2 10 days + Triamcinolo ne: 0.2mg/kg each, 3 days 4 1 Placebo x 10 days 0 5 × 10 4 Serovar 4 Placebo x 14 days 7 10 Cervix 7 E (MTW47 7) 5X 10 3 Placebo x 14 days 0 3 5 × 10 4 Serovar E (MTW47 7) 1X 8 3 Azithromyci n: 14mg/kg each, 5 days 0 Open in a separate window Pigtailed macaques entered in the experiment C. trachomatis serovar used to infect, site of inoculation, antibiotic treatment and number of samples collected Production of C. trachomatis proteome microarray chips The C. trachomatis protein microarray chips were prepared following a three steps process: 1) PCR amplification of the 894 open reading frames (ORF); 2) in vivo recombination cloning, and 3) in vitro transcription/translation followed by microarrays chip printing (Antigen Discovery, Inc., Irvine, CA).

Techniques: Infection, Membrane, Translocation Assay

Journal: Journal of proteomics

Article Title: Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques

doi: 10.1016/j.jprot.2014.05.009

Figure Lengend Snippet: Antibody responses in monkeys to the 20 immunodominant C. trachomatis antigens following antibiotic/placebo treatment

Article Snippet: At the time the experiments were performed combination therapy with different agents was included. table ft1 table-wrap mode="anchored" t5 caption a7 # Pigtaile d macaqu es Inoculati on site # serum samples before inoculati on Chlamy dia serovar # of inoculatio ns # serum samples after inoculati on # Pigtaile d macaqu es Treatment # serum sampl es after tx 15 Fallopian tubes 6 Doxycyclin e: 2.2mg/kg/d ay orally, 10 days Doxycyclin e: 16 9 6 × 10 6 Serovar D (PO124) 3X 13 1 2.2mg/kg/d ay orally, 10 days + Triamcinolo ne: 0.2mg/kg each, 3 days 1 2 Placebo x 10 days Doxycyclin 9 2 5 × 10 6 Serovar E 2X 3 2 e: 2.2mg/kg/d 3 (MTW47 7) ay orally, 10 days Doxycyclin e: 1 2.2mg/kg/d ay orally, 10 days Doxycyclin 1 4 6 × 10 6 Serovar E 2X 6 e: 2.2mg/kg/d ay orally, (MTW47 7) 2 10 days + Triamcinolo ne: 0.2mg/kg each, 3 days 4 1 Placebo x 10 days 0 5 × 10 4 Serovar 4 Placebo x 14 days 7 10 Cervix 7 E (MTW47 7) 5X 10 3 Placebo x 14 days 0 3 5 × 10 4 Serovar E (MTW47 7) 1X 8 3 Azithromyci n: 14mg/kg each, 5 days 0 Open in a separate window Pigtailed macaques entered in the experiment C. trachomatis serovar used to infect, site of inoculation, antibiotic treatment and number of samples collected Production of C. trachomatis proteome microarray chips The C. trachomatis protein microarray chips were prepared following a three steps process: 1) PCR amplification of the 894 open reading frames (ORF); 2) in vivo recombination cloning, and 3) in vitro transcription/translation followed by microarrays chip printing (Antigen Discovery, Inc., Irvine, CA).

Techniques:

Journal: Journal of proteomics

Article Title: Whole genome identification of C. trachomatis immunodominant antigens after genital tract infections and effect of antibiotic treatment of pigtailed macaques

doi: 10.1016/j.jprot.2014.05.009

Figure Lengend Snippet: The distribution of the predicted roles of the 20-immunodominant antigens is compared to the whole C. trachomatis serovar D and to all the reactive chlamydial antigens using the JCVI cellular role categories.

Article Snippet: At the time the experiments were performed combination therapy with different agents was included. table ft1 table-wrap mode="anchored" t5 caption a7 # Pigtaile d macaqu es Inoculati on site # serum samples before inoculati on Chlamy dia serovar # of inoculatio ns # serum samples after inoculati on # Pigtaile d macaqu es Treatment # serum sampl es after tx 15 Fallopian tubes 6 Doxycyclin e: 2.2mg/kg/d ay orally, 10 days Doxycyclin e: 16 9 6 × 10 6 Serovar D (PO124) 3X 13 1 2.2mg/kg/d ay orally, 10 days + Triamcinolo ne: 0.2mg/kg each, 3 days 1 2 Placebo x 10 days Doxycyclin 9 2 5 × 10 6 Serovar E 2X 3 2 e: 2.2mg/kg/d 3 (MTW47 7) ay orally, 10 days Doxycyclin e: 1 2.2mg/kg/d ay orally, 10 days Doxycyclin 1 4 6 × 10 6 Serovar E 2X 6 e: 2.2mg/kg/d ay orally, (MTW47 7) 2 10 days + Triamcinolo ne: 0.2mg/kg each, 3 days 4 1 Placebo x 10 days 0 5 × 10 4 Serovar 4 Placebo x 14 days 7 10 Cervix 7 E (MTW47 7) 5X 10 3 Placebo x 14 days 0 3 5 × 10 4 Serovar E (MTW47 7) 1X 8 3 Azithromyci n: 14mg/kg each, 5 days 0 Open in a separate window Pigtailed macaques entered in the experiment C. trachomatis serovar used to infect, site of inoculation, antibiotic treatment and number of samples collected Production of C. trachomatis proteome microarray chips The C. trachomatis protein microarray chips were prepared following a three steps process: 1) PCR amplification of the 894 open reading frames (ORF); 2) in vivo recombination cloning, and 3) in vitro transcription/translation followed by microarrays chip printing (Antigen Discovery, Inc., Irvine, CA).

Techniques:

Journal: Cancer discovery

Article Title: The rodent liver undergoes weaning-induced involution and supports breast cancer metastasis

doi: 10.1158/2159-8290.CD-16-0822

Figure Lengend Snippet: (A) Intracardiac metastasis model, Nullip (N), n=24; Inv2, n=25. (B) Percent mice with tumor cells in liver (p=0.03; Chi-squared, RR 1.6 [95% CI:0.9–9.6]); (C) Tumor Cell Latency. (D) Percent mice with tumor cells in lung (p=0.81), bone marrow (p=0.51), and brain (p=0.36), Chi-squared. (E) Representative H&E image of liver micro-metastasis and staining for Ki67, CD45, and Heppar-1/CK18; scale bars=25 µm. (F) Portal vein metastasis model, Nullip, n=18; Inv2, n=17; R, n=8. (G) Percent of mice with overt metastasis at study end (**p=0.001, RR 3.9 [95% CI: 1.3–11.6]; *p=0.03, RR 2.0 [1.08–3.66]; two-tailed Fisher’s exact). (H) Representative Ki67, CD45, and Heppar-1/CK18 staining on overt liver metastases (T) from Inv2 mice, dashed lines denote tumor border; scale bars=25 µm. (I) Frequency of liver metastasis in young breast cancer patients (≤45 years of age); N, n=185; PPBC<5, n=205; PPBC 5-<10, n=174 (p=0.038; multivariate logistic regression, OR=4.05 [95% CI:1.08–15.12]). (J) Subset analysis of site-specific metastases in women with metastatic disease (N, n=34; PPBC<10, n=83). Frequency of liver metastasis (p=0.04, one-sided Fisher’s Exact; p=0.058, two-sided Fisher’s Exact, OR: 4.12 [95% CI:0.90–18.94]), and lung (p=1.00), brain (p=1.00), & bone (p=0.11) metastasis by Fisher’s exact (see Table S6). (K) Model of the postpartum involuting liver pro-metastatic microenvironment.

Article Snippet: Open in a separate window Figure 4 Evidence for a pro-metastatic microenvironment in the postpartum liver (A) Intracardiac metastasis model, Nullip (N), n=24; Inv2, n=25. (B) Percent mice with tumor cells in liver (p=0.03; Chi-squared, RR 1.6 [95% CI:0.9–9.6]); (C) Tumor Cell Latency. (D) Percent mice with tumor cells in lung (p=0.81), bone marrow (p=0.51), and brain (p=0.36), Chi-squared. (E) Representative H&E image of liver micro-metastasis and staining for Ki67, CD45, and Heppar-1/CK18; scale bars=25 μm. (F) Portal vein metastasis model, Nullip, n=18; Inv2, n=17; R, n=8. (G) Percent of mice with overt metastasis at study end (**p=0.001, RR 3.9 [95% CI: 1.3–11.6]; *p=0.03, RR 2.0 [1.08–3.66]; two-tailed Fisher’s exact). (H) Representative Ki67, CD45, and Heppar-1/CK18 staining on overt liver metastases (T) from Inv2 mice, dashed lines denote tumor border; scale bars=25 μm. (I) Frequency of liver metastasis in young breast cancer patients (≤45 years of age); N, n=185; PPBC<5, n=205; PPBC 5-<10, n=174 (p=0.038; multivariate logistic regression, OR=4.05 [95% CI:1.08–15.12]). (J) Subset analysis of site-specific metastases in women with metastatic disease (N, n=34; PPBC<10, n=83).

Techniques: Staining, Two Tailed Test